Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells-Reference-Cited by-同舟云学术

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

Published:2010-12-13 Issue:3 Volume:152 Page:295-306
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Patz Michaela,Isaeva Polina,Forcob Nche,Müller Bianka,Frenzel Lukas P.,Wendtner Clemens-Martin,Klein Christian,Umana Pablo,Hallek Michael,Krause Günter

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08428.x/fullpdf

Reference46 articles.

1. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation;Beers;Blood,2008

2. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection;Beers;Blood,2010

3. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species;Bellosillo;Blood,2001

4. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies;Bornstein;Investigational New Drugs,2010

5. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab;Bowles;Blood,2006

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study;Virology Journal;2024-09-09

2. Obinutuzumab in Difficult to Treat Phospholipase A2 Receptor Positive Membranous Nephropathy: Our Experience at a Tertiary Care Center in North India;Indian Journal of Nephrology;2024-07-08

3. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells;Frontiers in Immunology;2024-04-04

4. Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies;Frontiers in Cell and Developmental Biology;2023-10-31

5. Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential;Cancers;2022-11-24